Premium
Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: The role of anti‐VEGF and anti‐EGFR antibodies
Author(s) -
Geva Ravit,
Prenen Hans,
Topal Baki,
Aerts Raymond,
Vannoote Jaarke,
Van Cutsem Eric
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21760
Subject(s) - medicine , colorectal cancer , chemotherapy , oncology , bevacizumab , metastasis , vegf receptors , cancer
In the treatment of metastatic colorectal cancer, the subset of patients with liver‐only metastases shows the greatest promise for prolonged survival and cure. Advances in surgery and medical treatment have encouraged multimodality treatment strategies and therefore require a true multidisciplinary approach. The current standard of care includes peri‐operative chemotherapy and surgery. The new era of biologically targeted therapy requires an in‐depth look at the possible efficacy and risks of adding these agents to the treatment protocol. J. Surg. Oncol. 2010;102:937–945. © 2010 Wiley‐Liss, Inc.